Edison Liu

Last updated
Edison Liu 2022.png

Edison Tak-Bun Liu an American physician-scientist, whose work focuses on cancer genomics, breast cancer biology, and translational medicine. He has held senior leadership roles in biomedical research institutions in the United States and Asia.

Contents

Liu is a professor at The Jackson Laboratory, where he served as president and chief executive officer and as director of the NCI-designated JAX Cancer Center from 2012 to 2021. He was the founding executive director of the Genome Institute of Singapore (GIS) from 2001 to 2011, as well as chairman of the Health Sciences Authority, and president of the Human Genome Organization (HUGO) from 2007 to 2013. [1] [2]

From 1997 to 2001, Liu was scientific director of the National Cancer Institute's Division of Clinical Sciences. Earlier in his career, at the University of North Carolina at Chapel Hill (1987–1996), he held leadership roles at the Lineberger Comprehensive Cancer Center, UNC School of Medicine, UNC School of Public Health, and the national clinical trials cooperative group, Cancer and Leukemia Group B (CALGB). [3] [4]

Early life and education

Edison T. Liu was born in Hong Kong in 1952. In 1957, he immigrated with his physician parents to the United States, settling in San Francisco, where his father practiced medicine in the city's Chinatown. [5]

Liu earned his Bachelor of Science degree in chemistry and psychology from Stanford University in 1973, and received a Doctor of Medicine from the Stanford University School of Medicine in 1978. He completed his medical internship (1978–1979) and residency (1979–1980) at Barnes Hospital, affiliated with Washington University in St. Louis.

He subsequently undertook a fellowship in medical oncology at Stanford University (1980–1982) and a fellowship in hematology at University of California San Francisco, Moffitt Hospital (1982–1985). [6] From 1983 to 1987, Liu was a postdoctoral fellow in the Department of Microbiology at the University of California at San Francisco, working in the laboratory of Nobel laureate J. Michael Bishop [7] where he conducted molecular research on oncogenes and their roles in cancer. [8]

Professional appointments

Institutional leadership

University of North Carolina at Chapel Hill

In 1987, Liu joined the faculty of the University of North Carolina at Chapel Hill (UNC) in the Department of Medicine and also held faculty appointments in epidemiology, biochemistry, and genetics. He established a program in breast cancer research and started the first laboratory of molecular epidemiology at the UNC School of Public Health. [8]

In 1992, Liu became director of the UNC Lineberger Comprehensive Cancer Center's Specialized Program of Research Excellence (SPORE) in breast cancer, one of the first awards of its kind to be awarded by the National Cancer Institute. [1] [9] [10] The program aimed to integrate cancer prevention, molecular epidemiology, clinical translational research, and laboratory-based studies, including research addressing racial disparities in breast cancer outcomes. [9] [10]

Liu’s research during this period focused on identifying novel protein kinases in breast cancer and on the molecular epidemiology of oncogene mutations. During his tenure at UNC, Liu's research led to the discovery and functional analysis of the AXL receptor tyrosine kinase and its ligand growth arrest-specific 6 (GAS6), which became a target of interest for cancer therapy (see Contributions to Scientific Research, below). [11]

National Cancer Institute

In 1996, Liu was appointed scientific director for the Division of Clinical Sciences at the National Cancer Institute (NCI) in Bethesda, Maryland. [12] In this role, he oversaw clinical and translational research within the NCI's intramural program and was responsible for integrating departments related to clinical research—including surgery, medicine, pediatrics, radiation oncology, dermatology, and pathology. During his tenure, Liu held a leadership role in planning for the new NIH Clinical Center and oversaw the establishment of the NCI's cDNA microarray facility, an early initiative supporting research on the functional genomics of cancer. [8] [12]

In 1999, Liu worked with Professor Patrick Johnston of Queen's University Belfast and other collaborators to establish the All-Ireland-NCI Cancer Consortium, a cooperative initiative linking cancer researchers, clinicians, and policymakers from the United States, Northern Ireland, and the Republic of Ireland. [13] [14] The Consortium aimed to improve cancer outcomes through coordinated research, education, and healthcare delivery, and played a significant role in advancing cancer control and building research capacity in Northern Ireland during a period of peace and reconciliation following the Good Friday Agreement. [13] The Consortium has been recognized for establishing lasting partnerships, joint training programs, and shared infrastructure, which have contributed to scientific discovery and improved patient care, and highlighted how international collaboration in cancer research could contribute to building partnerships across regions affected by social conflict. [13] In recognition of his work with the consortium, Liu was awarded an honorary doctorate by Queen's University Belfast in 2007. [15]

Genome Institute of Singapore

In 2001, Edison Liu was appointed founding executive director of the Genome Institute of Singapore, which was established as part of Singapore's national biomedical sciences initiative. [8] [16] During his tenure, the institute grew from a team of three to nearly 300 staff and became recognized internationally for its research in genomics, cancer biology, and systems biomedicine. [8]

Liu also directed the Pan-Asian SNP Consortium, an initiative that mapped human genetic diversity across Asia and produced publications on population genetics. [17] He also served as chairman of the Health Sciences Authority of Singapore, the country's regulatory agency for health products and medical services leading it through a series of regulatory reform, and was a founding member of Singapore's Bioethics Advisory Committee that established the foundational legal-ethical framework for Singapore's biomedical initiative. [15] [8] [18]

During this period, Liu participated in national initiatives related to biomedical research infrastructure, clinical translation, and higher education reform. In 2003, he received Singapore's Public Service Medal in recognition of his contributions during the SARS outbreak and was named among the individuals identified as having contributed to Singapore's national development in biographical and historical accounts. [19]

Following his work in Singapore, Liu published and lectured on the development of biomedical research ecosystems. His international service included election as president of the Human Genome Organisation (HUGO) for two terms and election as a foreign associate member of the European Molecular Biology Organization (EMBO). [20]

The Jackson Laboratory

In 2012, Liu was appointed president and chief executive officer of The Jackson Laboratory, an independent nonprofit biomedical research institution based in Bar Harbor, Maine. [21] [22] In addition to its basic research programs in genetics and genomics, the laboratory produces and distributes research mouse models and related services for the biomedical research community.

During Liu's tenure, The Jackson Laboratory expanded its research activities to include systems genomics, human genetics, and translational biomedical research. [23] [21] [24] From 2012 to 2021, The Jackson Laboratory's annual operating revenue increased from $136 million to more than $572 million, [25] its staff nearly doubled, [26] and business operations expanded nationally and internationally, including new campuses in Connecticut, California, China and Japan. [20] [21] [22] Liu oversaw the development of a $291 million genomic medicine campus in Farmington, Connecticut, establishing a base for translational research and precision medicine initiatives. [27] He also served as director of the JAX Cancer Center, a National Cancer Institute-designated Cancer Center. [26]

Liu's earlier experience in Singapore during the 2003 SARS outbreak provided a relevant operational context during the COVID-19 pandemic. He directed efforts at The Jackson Laboratory's Connecticut site to establish high-capacity SARS-CoV-2 testing facilities that supported state and national public health responses and the rapid production of mouse models to support vaccine development. [28] [29]

Liu also promoted coordination between The Jackson Laboratory's academic research programs and its research services operations, including the expansion of in vivo research services and patient-derived xenograft platforms. [3] [8] Liu's efforts are credited with strengthening the laboratory's position as a leader in both fundamental genetics and translational genomic medicine. [8] [22] He stepped down as president and chief executive officer in 2021 and was subsequently named president emeritus and honorary fellow, while continuing as a faculty member. He has an active cancer research laboratory in Farmington, Conn. [21] [26]

Scientific contributions

Liu's research focuses on cancer genomics, transcriptional regulation, oncogene discovery, cancer therapeutics, and genetic epidemiology with an emphasis on breast cancer. His work examines the molecular mechanisms involved in cancer development and progression, with a particular focus on the genomic architecture of tumors, the regulation of gene expression, the identification of novel cancer drivers, therapeutic response, and genetic risk factors. The following sections highlight major areas of Liu's research:

Systems genomics of cancer

Liu has published conceptual and methodological work on systems genomics, addressing approaches for integrating large-scale genomic data with clinical research and translational applications. He has authored and co-authored review articles and a book describing frameworks for applying systems-level analyses to cancer biology and medicine. [30] [31] [32] In experimental studies, Liu and collaborators reported that structural genomic alterations in breast cancer occur in non-random patterns and are associated with coordinated regulation of nearby genes. Their work examined how the genomic organization of oncogenes and tumor suppressor genes, as well as the balance between these elements, relates to cancer progression. His research group also investigated how mutations in specific cancer-associated genes, including BRCA1 , generate characteristic downstream mutational signatures, such as the tandem duplicator phenotype, through defined DNA repair mechanisms. They reported that cancer genomes are configured to support tumor growth not by single gene drivers but through combinatorial effects of tumor suppressors and oncogenes. [33] [34]

Genomics of transcriptional regulation

Liu's research examined genome-wide binding of transcription factors particularly estrogen receptor alpha (ERα), in human cells. In these studies, his group reported the combinatorial action of ERα, GATA3, and FOXA1 as central to estrogen-dependent gene regulation and chromatin organization. These factors promote loop formation in chromatin and coordinate the recruitment of other transcription factors, advancing the understanding of 3D genome organization in transcriptional control. The experimental and analytical approaches developed in this research have also been used in studies of other DNA-binding proteins and their role in chromatin architecture. [35] [36] [37]

Oncogene discovery in human cancers

Using functional genomic approaches, Liu and collaborators reported the identification and characterization of oncogenic elements involved in cancer biology, including the receptor tyrosine kinase AXL and its ligand growth arrest-specific 6 (GAS6). Subsequent studies have examined the role of AXL signaling in epithelial–mesenchymal transition and its relevance as a target for cancer therapy. Additional work from Liu's research group described other signaling and regulatory proteins implicated in cancer, including focal adhesion kinase (FAK), FRK/RAK, JMJD6, and SPINK family members. These studies contributed to the characterization of molecular pathways involved in tumor progression and therapeutic response. [38] [39] [40] [41]

Molecular cancer therapeutics

Liu's research examined relationships between genomic alterations in cancer and responses to anticancer therapies. In these studies, his group reported that HER2-positive breast cancers exhibited increased responsiveness to dose-intense doxorubicin therapy and that RAS-mutant acute myeloid leukemia showed differential responses to higher-dose cytarabine treatment. [42] [43] [44] Additional work from his group investigated mechanisms of adaptive resistance to platinum-based chemotherapy in triple-negative breast and ovarian cancers, including analyses of genomic and epigenomic alterations associated with therapeutic resistance. [45] In 2025, Liu and collaborators published research examining the role of host genetic factors in modulating responses to immune checkpoint inhibitor therapies. [46]

Cancer genetic epidemiology

Liu's research included studies in cancer genetic epidemiology, examining how genetic variation in biochemical pathways contributes to breast cancer risk. His group employed genome-wide association studies to analyze genetic susceptibility across multiple cancer types and participated in international efforts to map cancer-associated alleles. This work examined the role of polygenic variation in cancer susceptibility and risk assessment. [47] [48] [49]

Science, society, and economic development

Liu has written and spoken on the societal and economic dimensions of biomedical research, including topics related to research policy, institutional development, and international collaboration.

In 1999, Liu and Patrick G. Johnston helped establish the All-Ireland NCI Cancer Consortium, a collaborative initiative linking cancer researchers and clinicians in the United States, Northern Ireland, and the Republic of Ireland. Contemporary accounts described the consortium as operating during a period of political transition in Northern Ireland and as supporting cross-border research, training, and clinical collaboration. [50]

While in Singapore, Liu served as founding executive director of the Genome Institute of Singapore, which functioned as a central research institute within the country's national biomedical sciences initiative. He also participated in national efforts related to university-based research development, [51] contributed to the national legal framework incorporating bioethics, [52] [53] and the conceptualization of science as a tool in international diplomacy. [54] [55]

Following his return to the United States, Liu applied related approaches to institutional leadership during his tenure as president and chief executive officer of The Jackson Laboratory, where he oversaw the expansion of research programs and research infrastructure in genetics and genomic medicine. A major part of his focus was to enhance the economic impact of the institution to its host states of Maine, Connecticut, and California. [15] [8]

Drawing on these experiences, Liu has published and lectured on approaches to building biomedical research ecosystems and managing scientific institutions. He has also been invited to advise and speak globally on topics related to science administration, research infrastructure, and economic sustainability in biomedical research.

Science and creativity

Liu is also a jazz pianist, an activity he has pursued alongside his scientific career. In interviews and public lectures, he has described jazz improvisation as closely related to the creative process in science, both involving a blend of structure, exploration, and adaptability. [3] Liu has spoken publicly about the role of creativity in scientific inquiry and has lectured on the intersection of art and science. [5] [56] [57] In 2014, he received the Maine Creative Industries Award from the Maine Center for Creativity in recognition of his work linking creative practice and scientific research. [58]

Honors and awards

Personal Life

Liu lives with his wife on their small family farm, and they have three adult children. [5]

References

  1. 1 2 Hutchinson, Ezzie (1 June 2001). "Edison Liu—Director of the Genome Institute of Singapore". The Lancet Oncology. 2: 385–388. doi:10.1016/S1470-2045(00)00394-6.
  2. ↑ "Edison T. Liu". The Medicine Maker. Retrieved 2026-01-12.
  3. 1 2 3 Press Herald (4 May 2020). "Watch: Like a Boss Now: One-on-one with Dr. Edison Liu, President and CEO of The Jackson Laboratory". Press Herald. Retrieved 2026-01-12.
  4. ↑ Kevin, Brian (2019). "Dr. Edison Liu's Favorite Place". Down East. Retrieved 2026-01-12.
  5. 1 2 3 "Dr. Edison Liu". The Maine Mag. Retrieved 2025-01-12.
  6. ↑ Stevens, Shelby (2015). "The Future of Genomics and Breast Cancer According to Dr. Edison T. Liu". The Colgate Maroon-News. Retrieved 2026-01-12.
  7. ↑ "Jackson Laboratory's Edison Liu Is Keynote at 40th Annual Meeting of the Academy". Connecticut Academy of Science and Engineering. 11 May 2015. Retrieved 2026-01-12.
  8. 1 2 3 4 5 6 7 8 9 "Of Mice and Men: Edison Liu Leaves Singapore to Head Jackson Laboratory". Bio-IT World. 26 August 2011. Retrieved 2026-01-12.
  9. 1 2 "NIH RePORTER Project Information". NIH RePORTER. Retrieved 2026-01-12.
  10. 1 2 "NIH Grant P50-CA058223". Grantome. Retrieved 2026-01-12.
  11. ↑ O'Bryan, J. P.; Frye, R. A.; Cogswell, P. C.; Neubauer, A.; Kitch, B.; Prokop, C.; Espinosa, R.; Le Beau, M. M.; Earp, H. S.; Liu, E. T. (1991). "axl, a transforming gene isolated from primary human myeloid leukemia cells, encodes a novel receptor tyrosine kinase". Molecular and Cellular Biology. 11 (10): 5016–5031. PMC   361494 .
  12. 1 2 "Edison Liu leaves Singapore to head Jackson Lab". Science. 2011. Retrieved 2026-01-12.
  13. 1 2 3 Johnston, Patrick G.; Daly, Peter A.; Liu, Edison (1999). "The NCI All Ireland Cancer Conference". The Oncologist. 4 (4): 275–277. doi:10.1634/theoncologist.4-4-275.
  14. ↑ "25-Year Anniversary of the Ireland–Northern Ireland–NCI Cancer Consortium". National Cancer Institute. 2024. Retrieved 2026-01-12.
  15. 1 2 3 "The Jackson Laboratory appoints B. Edison Liu, B.M.D., as new president and CEO". BioSpace. 2012. Retrieved 2026-01-12.
  16. ↑ Cyranoski, David (2008). "Genomics takes hold in Asia". Nature. 456 (7218): 12. doi:10.1038/456012a.
  17. ↑ Sun, Shirley (2012). Deconstructing and reifying “Asian” and ethnicities in Asia: Exploring HUGO pan-Asian SNP Consortium's work.
  18. ↑ "Past Members". Bioethics Advisory Committee, Singapore. Retrieved 2026-01-12.
  19. ↑ Tng, Ying Hui (2015). Not Born in Singapore: Fifty Personalities Who Shaped the Nation. Singapore: Epigram Books. ISBN   978-9814655415.
  20. 1 2 "History". Human Genome Organization. Retrieved 2026-01-12.
  21. 1 2 3 4 "Edison Liu". The Jackson Laboratory. Retrieved 2026-01-12.
  22. 1 2 3 "Masters of Complexity: Edison Liu on the Future of the Mouse Model". Bio-IT World. Retrieved 2026-01-12.
  23. ↑ "Largest Employers in Maine". Q106.5 FM. Retrieved 2026-01-12.
  24. ↑ "Dr. Liu makes case for genomics and personalized medicine". CT Mirror. Retrieved 2026-01-12.
  25. ↑ "The Jackson Laboratory". ProPublica Nonprofit Explorer. Retrieved 2026-01-12.
  26. 1 2 3 "Jackson Lab president and CEO will step down next February". Mainebiz. Retrieved 2026-01-12.
  27. ↑ "JAX Labs surpasses 10-year goals in six years". CT Mirror. Retrieved 2026-01-12.
  28. ↑ "Jackson Laboratory for Genomic Medicine provides coronavirus testing to Connecticut residents". MetroHartford Alliance. Retrieved 2026-01-12.
  29. ↑ "The Jackson Laboratory to Provide Widescale COVID-19 Testing in Connecticut". LifeScienceHistory.com. Retrieved 2026-01-12.
  30. ↑ Liu, E. T. (2005). "Systems biology, integrative biology, predictive biology". Cell. 121 (4): 505–506.
  31. ↑ Liu, E. T.; Kutznesov, V. A.; Miller, L. D. (2006). "In the pursuit of complexity: Systems medicine in cancer biology". Cancer Cell. 9 (4): 245–247.
  32. ↑ Liu, E. T.; Lauffenberger, D. A. (2009). Systems Biomedicine: Concepts and Perspectives. Elsevier Academic Press.
  33. ↑ Willis, N. A.; Frock, R. L.; Menghi, F.; Duffey, E. E.; Panday, A.; Camacho, V.; Hasty, E. P.; Liu, E. T.; Alt, F. W.; Scully, R. (2017). "Mechanism of tandem duplication formation in BRCA1-mutant cells". Nature. 551 (7682): 590–595.
  34. ↑ Menghi, F.; Barthel, F. P.; Yadav, V.; Tang, M.; Ji, B.; Ruan, Y.; Scully, R.; Verhaak, R. G. W.; Jonkers, J.; Liu, E. T. (2018). "The tandem duplicator phenotype is a prevalent genome-wide cancer configuration driven by distinct gene mutations". Cancer Cell. 34 (2): 197–210.e5. PMC   6481635 .
  35. ↑ Fullwood, M. J.; Pan, Y. F.; Xu, H.; Liu, E. T.; Wei, C. L.; Cheung, E.; Ruan, Y. (2009). "An oestrogen-receptor-alpha-bound human chromatin interactome". Nature. 462 (7269): 58–64. doi:10.1038/nature08497.
  36. ↑ Kong, S. L.; Li, G.; Loh, S. L.; Sung, W. K.; Liu, E. T. (2011). "Cellular reprogramming by the conjoint action of ERα, FOXA1, and GATA3 to a ligand-inducible growth state". Molecular Systems Biology. 7: 526. PMC   3202798 .
  37. ↑ Tang, Z.; Luo, O. J.; Li, X.; Zheng, M.; Ruan, Y.; Liu, E. T. (2015). "CTCF-mediated human 3D genome architecture reveals chromatin topology for transcription". Cell. 163 (7): 1611–1627. PMC   4734140 .
  38. ↑ O'Bryan, J. P.; Frye, R. A.; Cogswell, P. C.; Neubauer, A.; Kitch, B.; Prokop, C.; Espinosa, R.; Le Beau, M. M.; Earp, H. S.; Liu, E. T. (1991). "axl, a transforming gene isolated from primary human myeloid leukemia cells, encodes a novel receptor tyrosine kinase". Molecular and Cellular Biology. 11 (10): 5016–5031. PMC   361494 .
  39. ↑ Varnum, B. C.; Young, C.; Elliott, G.; Garcia, A.; Bartley, T. D.; Fridell, Y. W.; Hunt, R. W.; Trail, G.; Clogston, C.; Toso, R. J.; Liu, E. T.; Yamane, H. K. (1995). "Axl receptor tyrosine kinase stimulated by the vitamin K-dependent protein encoded by growth-arrest-specific gene 6". Nature. 373 (6515): 623–626. PMID   7854420.
  40. ↑ Soon, W. W.; Miller, L. D.; Black, M. A.; Dalmasso, C.; Chan, X. B.; Pang, B.; Ong, C. W.; Salto-Tellez, M.; Desai, K. V.; Liu, E. T. (2011). "Combined genomic and phenotype screening reveals secretory factor SPINK1 as an invasion and survival factor associated with patient prognosis in breast cancer". EMBO Molecular Medicine. 3 (8): 451–464. PMC   3377086 .
  41. ↑ Gong, Z.; Li, Q.; Shi, J.; Liu, E. T.; Shultz, L. D.; Ren, G. (2022). "Lipid-laden lung mesenchymal cells foster breast cancer metastasis via metabolic reprogramming of tumor cells and natural killer cells". Cell Metabolism. 34 (12): 1960–1976.e9. doi:10.1016/j.cmet.2022.11.003. PMC   9819197 . PMID   36476935.
  42. ↑ Thor, A. D.; Berry, D. A.; Budman, D. R.; Muss, H. B.; Kute, T.; Henderson, I. C.; Barcos, M.; Cirrincione, C.; Edgerton, S.; Allred, C.; Norton, L.; Liu, E. T. (1998). "erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer". Journal of the National Cancer Institute. 90 (18): 1346–1360. PMID   9747866.
  43. ↑ Neubauer, A.; Maharry, K.; Mrózek, K.; Thiede, C.; Marcucci, G.; Paschka, P.; Mayer, R. J.; Larson, R. A.; Liu, E. T.; Bloomfield, C. D. (2008). "Patients with acute myeloid leukemia and RAS mutations benefit most from postremission high-dose cytarabine". Journal of Clinical Oncology. 26 (28): 4603–4609. PMC   2653132 . PMID   18559876.
  44. ↑ Jiang, X.; Tan, J.; Li, J.; Kivimae, S.; Yang, X.; Zhuang, L.; Lee, P. L.; Chan, M. T. W.; Stanton, L. W.; Liu, E. T.; Cheyette, B. R.; Yu, Q. (2008). "DACT3 is an epigenetic regulator of Wnt/beta-catenin signaling in colorectal cancer". Cancer Cell. 13 (6): 529–541. PMC   2577847 .
  45. ↑ Menghi, F.; Banda, K.; Kumar, P.; Straub, R.; Dobrolecki, L.; Rodriguez, I. V.; Yost, S. E.; Somlo, G.; Swisher, E. M.; Liu, E. T. (2022). "Genomic and epigenomic BRCA alterations predict adaptive resistance and response to platinum-based therapy in patients with triple-negative breast and ovarian carcinomas". Science Translational Medicine. 14 (652): eabn1926. PMC   9585706 .
  46. ↑ Skelly, D.; Graham, J.; Chang, M.; Stearns, T. M.; Poirion, O.; Zhang, J. G.; Grassmann, J. D. S.; Luo, D.; Flynn, W. F.; Courtois, E. T.; Menghi, F.; Liu, E. T. (2025). "Mapping the genetic landscape establishing a tumor immune microenvironment favorable for anti-PD-1". Cell Reports. 44 (5). doi:10.1016/j.celrep.2025.115698.
  47. ↑ Sotiriou, C.; Neo, S. Y.; McShane, L. M.; Korn, E. L.; Long, P. M.; Jazaeri, A.; Martiat, P.; Fox, S. B.; Harris, A. L.; Liu, E. T. (2003). "Breast cancer classification and prognosis based on gene expression profiles from a population-based study". Proceedings of the National Academy of Sciences of the United States of America. 100 (18): 10393–10398. PMC   193572 .
  48. ↑ Low, Y. L.; Li, Y.; Humphreys, K.; Thalamuthu, A.; Darabi, H.; Wedrén, S.; Bonnard, C.; Czene, K.; Iles, M. M.; Heikkinen, T.; Aittomäki, K.; Blomqvist, C.; Nevanlinna, H.; Hall, P.; Liu, E. T.; Liu, J. (2010). "Multi-variant pathway association analysis reveals the importance of genetic determinants of estrogen metabolism in breast and endometrial cancer susceptibility". PLOS Genetics. 6 (7): e1001012. doi:10.1371/journal.pgen.1001012. PMC   2895650 .{{cite journal}}: CS1 maint: article number as page number (link) CS1 maint: unflagged free DOI (link)
  49. ↑ Bei, J. X.; Li, Y.; Jia, W. H.; Feng, B. J.; Zhou, G.; Chen, L. Z.; Feng, Q. S.; Low, H. Q.; Zhang, H.; He, F.; Tai, E. S.; Kang, T.; Liu, E. T.; Liu, J.; Zeng, Y. X. (2010). "A genome-wide association study of nasopharyngeal carcinoma identifies three new susceptibility loci". Nature Genetics. 42 (7): 599–603. doi:10.1038/ng.601.
  50. ↑ "25-Year Anniversary of the Ireland–Northern Ireland–NCI Cancer Consortium". National Cancer Institute. 2024. Retrieved 2026-01-12.
  51. ↑ Tng, Ying Hui (2015). Not Born in Singapore: Fifty Personalities Who Shaped the Nation. Singapore: Epigram Books. ISBN   978-9814655415.
  52. ↑ Chan, Charmaine K. M.; Liu, Edison T. (2010). "The Impact of the Bioethics Advisory Committee on the Research Community in Singapore". In Elliott, John M.; Ho, W. Calvin; Lim, Sylvia S. N. (eds.). Bioethics in Singapore: The Ethical Microcosm. World Scientific.
  53. ↑ Kaan, Terry; Liu, Edison T., eds. (2007). Life Sciences: Law and Ethics – Recent Developments in Singapore. Singapore: Academy Publishing.
  54. ↑ Liu, Edison T. (2018). "Science Diplomacy: New Day or False Dawn". Análisis Político. 31 (94): 209–212. doi:10.15446/anpol.v31n94.78311.
  55. ↑ Liu, Edison T. (November 2007). "Ecology for Success in the Biomedical Sector". BioSpectrum.
  56. ↑ "Jackson Lab CEO to give lecture, piano recital in Portland on how to improve culture". Mainebiz. Retrieved 2025-01-12.
  57. ↑ "Dr. Edison Liu to speak on art and science at USM". News Center Maine. Retrieved 2025-01-12.
  58. ↑ "Society Notebook: Stars of art and science". Portland Press Herald. 30 November 2014.
  59. ↑ "Honorary Degree Citations". Commencement. 22 May 2016. Retrieved 2016-06-10.
  60. ↑ "EurekAlert news release". EurekAlert!. Retrieved 2025-01-12.


This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.